1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology
20 mars 2023 08h00 HE | Timber Pharmaceuticals
- Treatment with TMB-001 demonstrated greater proportions of participants achieving primary and key secondary endpoints versus vehicle regardless of the subtype of congenital ichthyosis - BASKING...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study in Congenital Ichthyosis
15 mars 2021 08h30 HE | Timber Pharmaceuticals
- Study is Evaluating TMB-001 (Topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder  - Company Awarded Final Tranche of $1.5 Million FDA Orphan Products Clinical Trials...